⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14127538 | 0.95 | — | — | |
| SCHEMBL27396 | 0.95 | — | — | |
| SCHEMBL2565625 | 0.90 | — | — | |
| Fluoride SCHEMBL15271706 | 0.90 | — | — | |
| SCHEMBL13593224 | 0.90 | — | — | |
| SCHEMBL18107428 | 0.86 | — | — | |
| SCHEMBL906865 | 0.86 | — | — | |
| SCHEMBL520884 | 0.82 | — | — | |
| SCHEMBL3222880 | 0.82 | — | — | |
| SCHEMBL70317 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105073742-B | FLAP conditioning agents | 詹森药业有限公司 | 2017-08-08 | — | — | CN | claimed |
| CN-105073742-A | Flap modulators | JANSSEN PHARMACEUTICA NV | 2015-11-18 | — | — | CN | claimed |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| EP-3562828-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4126879-B1 | N-PHENYL SUBSTITUTED INDOLE DERIVATIVES AS MYT1 INHIBITORS FOR THE TREATMENT OF CANCER | REPARE THERAPEUTICS INC (CA) | 2026-01-21 | — | — | EP | disclosed |
| US-12479834-B2 | Phenol compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| US-12435090-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | REPARE THERAPEUTICS INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-20250136604-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2025-05-01 | — | — | US | disclosed |
| WO-2025076235-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119735588-A | Cyclobutyl dihydroquinolines sulfonamide compounds | 美国安进公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-115697971-B | Cyclobutyl dihydroquinolines sulfonamide compounds | 美国安进公司 | 2025-01-28 | — | — | CN | disclosed |
| US-7932274-B2 | 3-indazolyl-4-pyridylisothiazoles | ELI LILLY AND COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2276759-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | Eli Lilly & Company (US) | 2011-01-26 | — | — | EP | disclosed |
| CN-101959883-A | 3-indazolyl-4-pyridylisothiazoles | LILLY CO ELI | 2011-01-26 | — | — | CN | disclosed |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-05 | — | — | US | disclosed |
| WO-2010086251-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
| US-20090253750-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | ELI LILLY AND COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009123855-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | ELI LILLY AND COMPANY (US) | 2009-10-08 | — | — | WO | disclosed |
| WO-2006000401-A1 | SUBSTITUTED OXAZINES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |